US Capitol Capsule: Patent rejections expected to rise under post-Myriad guidelines
This article was originally published in Scrip
Executive Summary
In laying down new guidelines for examining patent claims, the US Patent & Trademark Office (US PTO) has taken a broad interpretation of the US Supreme Court's unanimous ruling last June that declared a naturally occurring DNA segment is a product of nature and not patent eligible "merely because it has been isolated," legal experts said.